GH Research PLC (GHRS) - Net Assets
Based on the latest financial reports, GH Research PLC (GHRS) has net assets worth $359.49 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($372.35 Million) and total liabilities ($12.86 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check GHRS PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $359.49 Million |
| % of Total Assets | 96.55% |
| Annual Growth Rate | 197.85% |
| 5-Year Change | 0.91% |
| 10-Year Change | N/A |
| Growth Volatility | 1753.48 |
GH Research PLC - Net Assets Trend (2019–2025)
This chart illustrates how GH Research PLC's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market value of GH Research PLC.
Annual Net Assets for GH Research PLC (2019–2025)
The table below shows the annual net assets of GH Research PLC from 2019 to 2025. Also explore GHRS shareholders equity momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $279.70 Million | +56.30% |
| 2024-12-31 | $178.95 Million | -18.28% |
| 2023-12-31 | $218.97 Million | -12.35% |
| 2022-12-31 | $249.82 Million | -9.87% |
| 2021-12-31 | $277.18 Million | +4791.90% |
| 2020-12-31 | $5.67 Million | +1316.50% |
| 2019-12-31 | $400.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to GH Research PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 15403600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.55 Million | 0.55% |
| Other Comprehensive Income | $1.52 Million | 0.54% |
| Other Components | $431.06 Million | 154.11% |
| Total Equity | $279.70 Million | 100.00% |
GH Research PLC Competitors by Market Cap
The table below lists competitors of GH Research PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Guangdong Ellington Electronics Technology Co Ltd
SHG:603328
|
$1.97 Billion |
|
Sichuan Teway Food Group Co Ltd
SHG:603317
|
$1.97 Billion |
|
China Enterprise Co Ltd
SHG:600675
|
$1.97 Billion |
|
Gudang Garam Tbk
JK:GGRM
|
$1.97 Billion |
|
Ruentex Industries Ltd
TW:2915
|
$1.97 Billion |
|
Wenzhou Yihua Connector Co Ltd
SHE:002897
|
$1.97 Billion |
|
Spectrum Brands Holdings Inc
NYSE:SPB
|
$1.97 Billion |
|
Alsea S.A.B. de C.V
MX:ALSEA
|
$1.97 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GH Research PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 178,951,000 to 279,703,000, a change of 100,752,000 (56.3%).
- Net loss of 48,257,999 reduced equity.
- New share issuances of 150,000,000 increased equity.
- Other comprehensive income increased equity by 8,883,000.
- Other factors decreased equity by 9,873,001.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-48.26 Million | -17.25% |
| Share Issuances | $150.00 Million | +53.63% |
| Other Comprehensive Income | $8.88 Million | +3.18% |
| Other Changes | $-9.87 Million | -3.53% |
| Total Change | $- | 56.30% |
Book Value vs Market Value Analysis
This analysis compares GH Research PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.27x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 2010.40x to 6.27x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.01 | $28.72 | x |
| 2020-12-31 | $0.19 | $28.72 | x |
| 2021-12-31 | $5.33 | $28.72 | x |
| 2022-12-31 | $4.80 | $28.72 | x |
| 2023-12-31 | $4.21 | $28.72 | x |
| 2024-12-31 | $3.44 | $28.72 | x |
| 2025-12-31 | $4.58 | $28.72 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GH Research PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -17.25%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.03x
- Recent ROE (-17.25%) is above the historical average (-21.85%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -77.50% | 0.00% | 0.00x | 1.26x | $-350.00K |
| 2020 | -7.87% | 0.00% | 0.00x | 1.04x | $-1.01 Million |
| 2021 | -3.32% | 0.00% | 0.00x | 1.01x | $-36.92 Million |
| 2022 | -8.99% | 0.00% | 0.00x | 1.02x | $-47.44 Million |
| 2023 | -16.25% | 0.00% | 0.00x | 1.03x | $-57.48 Million |
| 2024 | -21.77% | 0.00% | 0.00x | 1.05x | $-56.86 Million |
| 2025 | -17.25% | 0.00% | 0.00x | 1.03x | $-76.23 Million |
Industry Comparison
This section compares GH Research PLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $249,490,347
- Average return on equity (ROE) among peers: -108.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GH Research PLC (GHRS) | $359.49 Million | -77.50% | 0.04x | $1.97 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $120.41 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $307.08 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.57 Billion |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $1.25 Million | -621.32% | 5.21x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.34 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $4.73 Billion |
About GH Research PLC
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II… Read more